Coenzyme Q10 and spinocerebellar ataxias

Movement Disorders

Volumn 30, Issue 2, 2015, Pages 214-220

  Lo, Raymond Y ^a   Figueroa, Karla P ^b   Pulst, Stefan M ^b   Lin, Chi Ying ^c   Perlman, Susan ^d   Wilmot, George ^e   Gomez, Christopher ^f   Schmahmann, Jeremy ^g   Paulson, Henry ^h   Shakkottai, Vikram G ^h   Ying, Sarah ⁱ   Zesiewicz, Theresa ^j   Bushara, Khalaf ^k   Geschwind, Michael ^l   Xia, Guangbin ^m   Subramony, S H ^m   Ashizawa, Tetsuo ^m   Kuo, Sheng Han ^c  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c Columbia University ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j UNIVERSITY OF SOUTH FLORIDA   (United States)

^k UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF FLORIDA   (United States)

more..

Author keywords

Coenzyme Q10; Neurodegeneration; Spinocerebellar ataxias; Statins

Indexed keywords

ALPHA TOCOPHEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RILUZOLE; UBIDECARENONE; VARENICLINE; UBIQUINONE;

ADULT; AGE; ARTICLE; ASSESSMENT OF HUMANS; CAG REPEAT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE ASSESSMENT; OUTCOME ASSESSMENT; PATIENT HEALTH QUESTIONNAIRE 9; PRIORITY JOURNAL; SCALE FOR ASSESSMENT AND RATING OF ATAXIA; SPINOCEREBELLAR ATAXIA TYPE 1; SPINOCEREBELLAR ATAXIA TYPE 2; SPINOCEREBELLAR ATAXIA TYPE 3; SPINOCEREBELLAR ATAXIA TYPE 6; SPINOCEREBELLAR DEGENERATION; UNIFIED HUNTINGTON DISEASE RATING SCALE; UNIFIED HUNTINGTON'S DISEASE RATING SCALE PART IV; UNSPECIFIED SIDE EFFECT; AGED; ANALOGS AND DERIVATIVES; DISEASE COURSE; HUNTINGTON DISEASE; MIDDLE AGED; ONSET AGE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; SPINOCEREBELLAR ATAXIAS; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPINOCEREBELLAR ATAXIAS; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; UBIQUINONE;

EID: 84922240709     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26088     Document Type: Article

References (28)

1. Dürr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 2010;9:885-894.
2. Jacobi H, Bauer P, Giunti P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology 2011;77:1035-1041.
3. Schmitz-Hübsch T, Montcel du ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006;66:1717-1720.
4. Schmitz-Hübsch T, Fimmers R, Rakowicz M, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 2010;74:678-684.
5. Sánchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999;22:623-633.
6. Chou AH, Yeh TH, Kuo YL, et al. Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL. Neurobiol Dis 2006;21:333-345.
7. Wang HL, Yeh TH, Chou AH, et al. Polyglutamine-expanded ataxin-7 activates mitochondrial apoptotic pathway of cerebellar neurons by upregulating Bax and downregulating Bcl-x(L). Cell Signal 2006;18:541-552.
8. Chou AH, Lin AC, Hong KY, et al. p53 activation mediates polyglutamine-expanded ataxin-3 upregulation of Bax expression in cerebellar and pontine nuclei neurons. Neuroch Int 2011;58:145-152.
9. Artuch R, Brea-Calvo G, Briones P, et al. Cerebellar ataxia with coenzyme Q10 deficiency: diagnosis and follow-up after coenzyme Q10 supplementation. J Neurol Sci 2006;246:153-158.
10. Pineda M, Montero R, Aracil A, et al. Coenzyme Q(10)-responsive ataxia: 2-year-treatment follow-up. Mov Disord 2010;25:1262-1268.
11. Dueñas AM, Goold R, Giunti P. Molecular pathogenesis of spinocerebellar ataxias. Brain 2006;129:1357-1370.
12. Underwood BR, Rubinsztein DC. Spinocerebellar ataxias caused by polyglutamine expansions: a review of therapeutic strategies. Cerebellum 2008;7:215-221.
13. Wang Q, Yan J, Chen X, et al. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 2011;230:27-34.
14. Pac-Soo C, Lloyd DG, Vizcaychipi MP, Ma D. Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration. J Alzheimers Dis 2011;27:1-10.
15. Lee YC, Lin CH, Wu RM, et al. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 2013;81:410-416.
16. Karasinska JM, Hayden MR. Cholesterol metabolism in Huntington disease. Nat Rev Neurol 2011;7:561-572.
17. Behl C, Moosmann B. Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. Free Radic Biol Med 2002;33:182-191.
18. Anheim M, Tranchant C, Koenig M. The autosomal recessive cerebellar ataxias. New Engl J Med 2012;366:636-646.
19. Zesiewicz TA, Greenstein PE, Sullivan KL, et al. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 2012;78:545-550.
20. Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 2010;74:839-845.
21. Schmitz-Hübsch T, Coudert M, Tezenas du Montcel S, et al. Depression comorbidity in spinocerebellar ataxia. Mov Disord 2011;26:870-876.
22. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19:117-125.
23. Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion 2007;7(Suppl):S168-S174.
24. Schöls L, Amoiridis G, Büttner T, Przuntek H, Epplen JT, Riess O. Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes? Ann Neurol 1997;42:924-932.
25. de Castilhos RM, Furtado GV, Gheno TC, et al. Spinocerebellar ataxias in brazil-frequencies and modulating effects of related genes. Cerebellum 2014;13:17-28.
26. Ashizawa T, Figueroa KP, Perlman SL, et al. Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet J Rare Dis 2013;8:177.
27. Wang HL, Chou AH, Lin AC, Chen SY, Weng YH, Yeh TH. Polyglutamine-expanded ataxin-7 upregulates Bax expression by activating p53 in cerebellar and inferior olivary neurons. Exp Neurol 2010;224:486-494.
28. Simon DK, Zheng K, Velázquez L, et al. Mitochondrial complex I gene variant associated with early age at onset in spinocerebellar ataxia type 2. Arch Neurol 2007;64:1042-1044.